Registration
 
All news
Top Stories
Editors' Picks
Crypto News
Financial News
Currencies
Market Voices
Billionaires
Companies
Regulators News
Elena Nikulina
Elena Nikulina

FDA designations and clinical progress drive Atossa Therapeutics Q1 2026 financial report

FDA designations and clinical progress drive Atossa Therapeutics Q1 2026 financial report
Atossa Q1 2026 earnings, FDA nod

Atossa Therapeutics released its financial results for the first quarter of 2026, detailing continued progress in its (Z)-endoxifen development programs targeting oncology and rare diseases.

The company reported new FDA designations for rare disease indications, ongoing clinical advancement in breast cancer trials, and expansion of its development pipeline. These milestones underscore Atossa Therapeutics' commitment to accelerating drug development across multiple therapeutic areas.

Atossa previously advanced its Z-endoxifen pipeline with key U.S. FDA designations in oncology. The company has also presented endoxifen as a novel approach for treating Duchenne muscular dystrophy. These initiatives reflect Atossa's focus on developing targeted therapies for both cancer and rare diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Five years with Bitcoin: How El Salvador changed after legalizing BTC
  • By Eugene Komchuk
  • 12 hours ago
Five years with Bitcoin: How El Salvador changed after legalizing BTC
Editors' Picks
Crypto on the court: How NBA Finals became a showcase for Ledger
  • By Anastasiia Chabaniuk
  • Yesterday
Crypto on the court: How NBA Finals became a showcase for Ledger
Editors' Picks
How to build wealth from scratch in 3 practical steps
  • By Johnathan Maverick
  • 08.06.2026
How to build wealth from scratch in 3 practical steps
Editors' Picks
All Editors' Top Picks

Latest Atossa News

Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts
  • By Elena Nikulina
  • 08.06.2026
Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts
Companies
#Atossa
Atossa Therapeutics unveils findings on complexity of Duchenne muscular dystrophy beyond protein loss
  • By Igor Krasulya
  • 04.06.2026
Atossa Therapeutics unveils findings on complexity of Duchenne muscular dystrophy beyond protein loss
Companies
#Atossa
Atossa Therapeutics convenes leading experts for Endoxifen therapy virtual session
  • By Ivan Andriyenko
  • 22.05.2026
Atossa Therapeutics convenes leading experts for Endoxifen therapy virtual session
Companies
#Atossa
All Atossa News
  • Eugene Komchuk
  • 12 hours ago
Five years with Bitcoin: How El Salvador changed after legalizing BTC
  • Anastasiia Chabaniuk
  • Yesterday
Crypto on the court: How NBA Finals became a showcase for Ledger
  • Johnathan Maverick
  • 08.06.2026
How to build wealth from scratch in 3 practical steps
  • Eugene Komchuk
  • 08.06.2026
Kospi Index crash: Why South Korean market fell alongside AI stocks
  • Mira Kyivska
  • 07.06.2026
Bitcoin or Ferrari: Which investment is better?
  • Jose Antonio Gastelum
  • 10 min ago
Brian Armstrong: Coinbase approved to offer global crypto perpetuals in U.S.
  • Ivan Andriyenko
  • 10 min ago
Coca-Cola holds at peak while crypto and tech slide, Charlie Bilello notes
  • Mikhail Vnuchkov
  • 15 min ago
Proshares sought Lehman approval for leveraged ETFs in 2004, Jared Dillian notes
  • Yulia Slavina
  • 25 min ago
Keith McCullough: Long Only portfolio declined 11 bps amid aggressive Quad Shift
  • Hlib Chabaniuk
  • 25 min ago
Gabor Gurbacs: Domino’s Pizza no longer top performing long term investment
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Olga Shendetskaya
  • 6 hours ago
Hot CPI report puts new pressure on U.S. stocks
Hot CPI report puts new pressure on U.S. stocks
  • Igor Krasulya
  • 7 hours ago
Kalshi adds XRP to regulated perpetual futures market
Kalshi adds XRP to regulated perpetual futures market
  • Olga Shendetskaya
  • 8 hours ago
Global bond sales climb as defense spending and refinancing needs grow
Global bond sales climb as defense spending and refinancing needs grow
  • Hanna Syniavska
  • 10 hours ago
SoftBank shares fall 8% as OpenAI-backed loan talks stall
SoftBank shares fall 8% as OpenAI-backed loan talks stall
  • Andrey Mastykin
  • 11 hours ago
CLARITY Act talks hit new obstacles in Senate
CLARITY Act talks hit new obstacles in Senate
Live News
  • Anton Kharitonov
  • Now
Alphabet remains under pressure as AI drives growth outlook
  • Mykhailo Ihnatenko
  • Now
Tesla tests investor confidence amid tech sector sell-off
  • Anton Kharitonov
  • Now
Microsoft tests major support as pressure on shares persists after record expectations
  • Mykhailo Ihnatenko
  • Now
AMD retreats as AI rally cools and investors take profits
  • Anton Kharitonov
  • Now
Apple continues to decline as capex weighs on the stock
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR